9th International Science Congress (ISC-2019).  International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

NF1 Mutations and Clinical Manifestations in Neurofibromatosis Type 1 Patients in Tamil Nadu, South India

Author Affiliations

  • 1Department of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore-641046, India

Int. Res. J. Biological Sci., Volume 5, Issue (8), Pages 38-44, August,10 (2016)


Neurofibromatosis type 1 (NF1) is a genetic disorder affecting approximately 1 in 3000 individuals. It is caused by heterozygous inactivation of the NF1 a tumor suppressor gene or deletions of the entire NF1 gene. This study exemplifies the clinical heterogeneity of 13 Indian patients with NF1 and highlights the variations in sites and types of mutations in NF1 gene in this population. The DNA was extracted from the blood samples and the entire coding region of NF1 gene was amplified and sequenced by the Sanger method. In the present study, the frequencies of neurofibromas and plexiform neurofibromas were 92.3% and 30.7% respectively. 84.6% had a short stature and 38.5% had a macrocephaly. Café-au-lait spots were in all the cases while scoliosis was in only 2 patients. 53.8% had a frequent headache and 23% had facial dysmorphism. All NF1 mutations identified in 11 patients in our study population have been reported in previous studies and no novel mutation has been detected. NF1 mutations were detected in exons 4, 13, 21, 29, and 46. The frequencies of point mutations were 36.4% nonsense, 36.4% missense and 27.2% frameshift. Variable expression of the same NF1 mutation made identification of genotype-phenotype correlations a daunting task.


  1. McCormick F. (1995)., Ras signaling and NF1., Current opinion in genetics & development, 5(1), 51-55.
  2. Ferner R. E., Huson S. M., Thomas N., Moss C., Willshaw H., Evans D. G. and Kirby A. (2007)., Guidelines for the diagnosis and management of individuals with neurofibromatosis 1., Journal of medical genetics, 44(2), 81-88.
  3. Weiss B., Bollag G. and Shannon K. (1999)., Hyperactive Ras as a therapeutic target in neurofibromatosis type 1., American journal of medical genetics, 89(1), 14-22.
  4. Listernick R., Ferner R. E., Liu G. T. and Gutmann D. H. (2007)., Optic pathway gliomas in neurofibromatosis‐1: Controversies and recommendations., Annals of neurology, 61(3), 189-198.
  5. Kluwe L., Siebert R., Gesk S., Friedrich R. E., Tinschert S., Kehrer‐Sawatzki H. and Mautner V. F. (2004)., Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene., Human mutation, 23(2), 111-116.
  6. Upadhyaya M., Huson S. M., Davies M., Thomas N., Chuzhanova N., Giovannini S. and Consoli C. (2007)., An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c. 2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation., The American Journal of Human Genetics, 80(1), 140-151.
  7. Miller S. A., Dykes D. D. and Polesky H. F. R. N. (1988)., A simple salting out procedure for extracting DNA from human nucleated cells., Nucleic acids research, 16(3), 1215.
  8. De Bella K., Szudek J. and Friedman J. M. (2000)., Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children., Pediatrics, 105(3), 608-614.
  9. Friedman J. M. (Ed.). (1999)., Neurofibromatosis: phenotype, natural history, and pathogenesis., Johns Hopkins University Press.
  10. Evans D. G. R., Baser M. E., McGaughran J., Sharif S., Howard E. and Moran A. (2002)., Malignant peripheral nerve sheath tumours in neurofibromatosis 1., Journal of medical genetics, 39(5), 311-314.
  11. Hyman S. L., Shores E. A. and North K. N. (2006)., Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit–hyperactivity disorder., Developmental Medicine & Child Neurology, 48(12), 973-977.
  12. Ars E., Kruyer H., Morell M., Pros E., Serra E., Ravella A. and Lazaro C. (2003)., Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients., Journal of medical genetics, 40(6), e82-e82.
  13. Ko J. M., Sohn Y. B., Jeong S. Y., Kim H. J. and Messiaen L. M. (2013)., Mutation spectrum of NF1 and clinical characteristics in 78 Korean patients with neurofibromatosis type 1., Pediatric neurology, 48(6), 447-453.
  14. Zeng K., Zhang Q. G., Liang L. P. and Liang Y. H. (2014)., Three Novel Missense Mutations of NF1 in Neurofibromatosis Type 1 Patient., Journal of Clinical & Experimental Dermatology Research, 2014.
  15. Rodríguez A. D., Moreno G. M., Santo-Domingo Y. M., Martín A. H., Roca J. E. S., Rojas M. R. F. and Argente J. (2015)., Características fenotípicas y genéticas en la neurofibromatosis tipo 1 en edad pediátrica., Anales de Pediatría, 83(3), 173-182, Elsevier Doyma.
  16. Huson S. U. S. A. N., Jones D. Y. L. A. N. and Beck L. (1987)., Ophthalmic manifestations of neurofibromatosis., British Journal of Ophthalmology, 71(3), 235-238.
  17. Schindeler A. and Little D. G. (2008)., Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1)., Bone, 42(4), 616-622.
  18. Stevenson D. A., Zhou H., Ashrafi S., Messiaen L. M., Carey J. C., D’Astous J. L. and Viskochil D. H. (2006)., Double inactivation of NF1 in tibial pseudarthrosis., The American Journal of Human Genetics, 79(1), 143-148.
  19. Lin A. E., Birch P. H., Korf B. R., Tenconi R., Niimura M., Poyhonen M. and Bonioli E. (2000)., Cardiovascular malformations and other cardiovascular abnormalities in neurofibromatosis 1., American journal of medical genetics, 95(2), 108-117.
  20. Heuschkel R., Kim S., Korf B., Schneider G. and Bousvaros A. (2001)., Abdominal migraine in children with neurofibromatosis type 1: a case series and review of gastrointestinal involvement in NF1., Journal of pediatric gastroenterology and nutrition, 33(2), 149-154.